4T1-hPD-L1

Export PDF

Strain Information

Cell Line

4T1-Cd274em1(hPD-L1)Smoc

Cat. NO.

NM-S07-TM07

Model Description

PD-L1 gene humanized 4T1 cell line

Strain State

Validation of tumorigenic capacity completed

Validation Data

image.png

Fig 1. hPD-L1 expression on in vitro cultured cells of H22-hPD-L1


image.png

Fig 2. hPD-L1(BALB/c) mice were inoculated with H22-hPD-L1 subcutaneously at 1×106 cells/mouse inoculum for tumor development


image.png

Fig 3. hPD-L1 expression in tumors after in vivo growth of H22-hPD-L1 in wild type hPD-L1(BALB/c) mouse. The tumors were collected at day 11 post tumor cell inoculation.


image.png

Fig 4. hPD-L1 expression in tumors after in vivo growth of H22-hPD-L1 in wild type hPD-L1(BALB/c) mouse. The tumors were collected at day 21 post tumor cell inoculation.


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more